Caraco Denied Quick Win On Prandin IP Misuse Claim

Law360, New York (February 25, 2011, 3:08 PM EST) -- A federal judge in Michigan on Thursday refused to analyze Caraco Pharmaceutical Laboratories Ltd.'s contention that Novo Nordisk A/S misused its patent for the diabetes drug Prandin, finding the matter inappropriate to consider in light of pending appeals.

Judge Avern Cohn of the U.S. District Court for the Eastern District of Michigan denied without prejudice Caraco's renewed motion for summary judgment on patent misuse, stating that it would be inappropriate to weigh in on the issue while appeals filed by both parties in the long-running patent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.